Specifically, antagonizing NMDA receptors in the brainstem has been associated with an increase in short-term food intake 6,7
doi: 10.1002/ejhf.1596 65 SolomonSDMcMurrayJJVClaggettBde BoerRADeMetsDHernandezAFet al
PMID: Summary Keywords autoimmune diseases, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, incretin-based therapy, psoriasis, real-world evidence Citation Chiang Y-L, Li T-H, Fang Y-W, Liu Y-F, Wu J and Tsai M-H (2026) Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation
CMLD013075, an Hsp90 inhibitor, demonstrates equal growth inhibitory potency against both drug-resistant and wild strains, exhibiting synergistic effects when paired with fluconazole [129]
Adverse effect management requires awareness of centrally mediated symptoms
GLP-1 drugs are already nudging blood sugar down